Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Chiara Bazzichetto, Fabiana Conciatori, Claudio Luchini, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 309-309
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e002068-e002068
Open Access | Times Cited: 133
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Quan Liu, Yanhong Duo, Jianye Fu, et al.
Nano Today (2020) Vol. 36, pp. 101023-101023
Closed Access | Times Cited: 73
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 10
Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy
Sara Fanijavadi, Mads Thomassen, Lars Henrik Jensen
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 515-515
Open Access | Times Cited: 1
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla, et al.
Cancer Chemotherapy and Pharmacology (2019) Vol. 83, Iss. 5, pp. 975-991
Closed Access | Times Cited: 74
Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
Kinga B. Stopa, Agnieszka A. Kusiak, Mateusz D. Szopa, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 44
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology
Chiara Bazzichetto, Claudio Luchini, Fabiana Conciatori, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8841-8841
Open Access | Times Cited: 43
Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1
Bekesho Geleta, Faten Shehadeh-Tout, Syer Choon Lim, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 3, pp. 101608-101608
Open Access | Times Cited: 28
Nanoparticle-based immunotherapy of pancreatic cancer
Gaetan Aime Noubissi Nzeteu, Bernhard F. Gibbs, Nika Kotnik, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 20
Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians
Dimitrios Giannis, Demetrios Moris, Andrew S. Barbas
Cancers (2021) Vol. 13, Iss. 5, pp. 1071-1071
Open Access | Times Cited: 26
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
Wei Liu, Mohamad‐Gabriel Alameh, June F. Yang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14504-14504
Open Access | Times Cited: 15
Principles of Palliative and Supportive Care in Pancreatic Cancer: A Review
Robert Mazur, Jan Trna
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2690-2690
Open Access | Times Cited: 8
Malignant epithelial/exocrine tumors of the pancreas
Claudio Luchini, Federica Grillo, Matteo Fassan, et al.
Pathologica (2020) Vol. 112, Iss. 3, pp. 210-226
Open Access | Times Cited: 21
Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer
Xiaoli Yin, Lingming Kong, Peng Liu
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 18
GABRP is a potential prognostic biomarker and correlated with immune infiltration and tumor microenvironment in pancreatic cancer
Yihui Yang, Liwen Ren, Sha Li, et al.
Translational Cancer Research (2022) Vol. 11, Iss. 4, pp. 649-668
Open Access | Times Cited: 11
Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
Manxiong Dai, Raja Jahanzaib, Yan Liao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Enhancing Oral Performance of Paclitaxel Lipid‐Mimic Prodrug via Modulating Type of Fatty Acids
Yifan Miao, Qing Ye, Ming‐yang Zhang, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 19
Closed Access | Times Cited: 5
Risk factors of pancreatic cancer and their possible uses in diagnostics
Jitka Lang, Lumír Kunovský, Zdeněk Kala, et al.
Neoplasma (2020) Vol. 68, Iss. 02, pp. 227-239
Open Access | Times Cited: 13
Tumour-Derived Reg3A Educates Dendritic Cells to Promote Pancreatic Cancer Progression
Jie Guo, Mengfan Liao, Xianmin Hu, et al.
Molecules and Cells (2021) Vol. 44, Iss. 9, pp. 647-657
Open Access | Times Cited: 12
C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients
Vanessa Bonazzi, Lauren G. Aoude, Sandra Brosda, et al.
Asia-Pacific Journal of Clinical Oncology (2023)
Open Access | Times Cited: 4
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
Francesca Simionato, Camilla Zecchetto, Valeria Merz, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 11
Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data
Fabio Bagante, Gaya Spolverato, Andrea Ruzzenente, et al.
European Journal of Cancer (2021) Vol. 148, pp. 348-358
Closed Access | Times Cited: 10
Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approach
Wei Liu, Mohamad‐Gabriel Alameh, June F. Yang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance
Apostolis Papaefthymiou, Aris Doukatas, Michail Galanopoulos
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 5, pp. 101911-101911
Closed Access | Times Cited: 5
The implication of liquid biopsies to predict chemoresistance in pancreatic cancer
Elisabetta Pietri, Rita Balsano, Matilde Coriano, et al.
Cancer Drug Resistance (2021)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top